Karyopharm Therapeutics reported $37.34M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbott ABT:US $ 2.74B 44M
Abbvie ABBV:US $ 3.13B 73M
Amgen AMGN:US $ 1.33B 99M
AstraZeneca AZN:LN 3.27B 209M
Astrazeneca AZN:US 3.27B 209M
Avrobio Inc AVRO:US 8.9M 1.27M
Biocryst Pharmaceuticals BCRX:US $ 38.02M 3.74M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Eli Lilly And LLY:US $ 1.63B 67.2M
Enanta Pharmaceuticals ENTA:US $ 12.93M 2.45M
Epizyme EPZM:US $ 24.11M 3.09M
GlaxoSmithKline GSK:LN 1.96B 726M
Johnson & Johnson JNJ:US $ 6.23B 288M
Karyopharm Therapeutics KPTI:US $ 37.34M 1.43M
Macrogenics MGNX:US $ 13.67M 2.58M
Merk MRK:US $ 2.42B 118M
Mirati Therapeutics MRTX:US $ 54.23M 277K
Nektar Therapeutics NKTR:US $ 21.44M 5.9M
Novartis NOVN:VX 3.59B 91M
Novartis NVS:US 3.59B 91M
Pfizer PFE:US $ 3.2B 506M
Regeneron Pharmaceuticals REGN:US $ 476.3M 26.3M
Sangamo Biosciences SGMO:US $ 15.09M 185K
Takeda 4502:JP 231.48B 8.05B
Tg Therapeutics TGTX:US $ 12.64M 7.97M
Ultragenyx Pharmaceutical RARE:US $ 68.14M 825K
Xencor XNCR:US $ 11.09M 182K
YTE INCY:US $ 253.28M 43.69M